Figure 1. Study Design: After enrollment (Visit 0), a
matching drug placebo was administered subcutaneously at visit 1.
Benralizumab 30mg was then administrated subcutaneously at three
consecutive monthly intervals (visits 2, 3, and 4). Clinical outcomes
(UAS7, CU-QoL) were recorded at each visit. Blood samples were collected
at each visit for total and differential blood cell counts. Blood was
also collected at Visits 2 and 5 for RNA-sequencing. Skin biopsies (from
lesional and non-lesional skin) were obtained at visit2
(post-placebo/pre-benralizumab treatment) and again at visit 5 (4 weeks
after last benralizumab treatment) from all CSU patients for histology
and RNA-sequencing. Similar skin and blood samples were obtained from 5
non-CSU healthy controls at visit 0 only. Vital sign parameters were
measured at every visit. RNA-extracted from blood and skin biopsies were
stored at -80° C for later use.